Why is this ASX small cap ripping 37% ahead on Tuesday?

MotleyFool08-13

LTR Pharma Ltd (ASX: LTP) shares are on fire on Tuesday afternoon. At the time of writing, the ASX small cap share is up 37% to a record high of $1.32. Why is this ASX small cap rocketing? Investors ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2459691146?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-13 12:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2459691146","market":"us","top_or_hot":-1,"title":"Why is this ASX small cap ripping 37% ahead on Tuesday?","media":"MotleyFool","content":"<div>\n<p>LTR Pharma Ltd (ASX: LTP) shares are on fire on Tuesday afternoon. At the time of writing, the ASX small cap share is up 37% to a record high of $1.32. Why is this ASX small cap rocketing? Investors ...</p>\n\n<a href=\"https://www.fool.com.au/2024/08/13/why-is-this-asx-small-cap-ripping-37-ahead-on-tuesday/\">Source Link</a>\n\n</div>\n","source":"motleyfoolau_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why is this ASX small cap ripping 37% ahead on Tuesday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy is this ASX small cap ripping 37% ahead on Tuesday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-13 12:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com.au/2024/08/13/why-is-this-asx-small-cap-ripping-37-ahead-on-tuesday/><strong>MotleyFool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>LTR Pharma Ltd (ASX: LTP) shares are on fire on Tuesday afternoon. At the time of writing, the ASX small cap share is up 37% to a record high of $1.32. Why is this ASX small cap rocketing? Investors ...</p>\n\n<a href=\"https://www.fool.com.au/2024/08/13/why-is-this-asx-small-cap-ripping-37-ahead-on-tuesday/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4213","symbol_name":"石油与天然气的勘探与生产","start_time":0,"source_url":"https://www.fool.com.au/2024/08/13/why-is-this-asx-small-cap-ripping-37-ahead-on-tuesday/","article_id":"2459691146","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2459691146","pubTimestamp":1723522983,"sourceInfo":{"source_id":"motleyfoolau_stock","name":"MotleyFool"},"weMediaInfo":null,"summary":"LTR Pharma Ltd  shares are on fire on Tuesday afternoon. At the time of writing, the ASX small cap share is up 37% to a record high of $1.32. Why is this ASX small cap rocketing?Investors have been fighting to get hold of the pharmaceutical company's shares this morning following the release of a promising announcement. According to the release, the company has entered into a co-development agreement for its Sponton product for global markets. The agreement has been secured with Aptar Pharma , which is a global leader in drug delivery systems, services, and active material science solutions. The ASX small cap notes that Aptar Pharma has supported numerous market authorisation holders in obtaining their combination drug-device product approvals incorporating Aptar's nasal delivery systems. This includes from regulatory agencies such as the U.S. Food and Drug Administration . What is the agreement?","collect":0,"end_time":0,"defaultTopTitle":"fool.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4213":"石油与天然气的勘探与生产","TGA":"Transglobe Energy Corp","BK7096":"制药","BK4126":"金属与玻璃容器","ATR":"Aptar","LTP.AU":"LTR PHARMA LTD","TGA.AU":"Thorn GroupLtd","BK7001":"电脑与电子产品零售"},"translate_title":"为什么澳大利亚证券交易所小盘股周二上涨37%？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATR":1,"LTP.AU":1,"TGA":1,"TGA.AU":1},"content_text":"LTR Pharma Ltd (ASX: LTP) shares are on fire on Tuesday afternoon. At the time of writing, the ASX small cap share is up 37% to a record high of $1.32. Why is this ASX small cap rocketing? Investors have been fighting to get hold of the pharmaceutical company's shares this morning following the release of a promising announcement. According to the release, the company has entered into a co-development agreement for its Sponton product for global markets. The agreement has been secured with Aptar Pharma (NYSE: ATR), which is a global leader in drug delivery systems, services, and active material science solutions. The ASX small cap notes that Aptar Pharma has supported numerous market authorisation holders in obtaining their combination drug-device product approvals incorporating Aptar's nasal delivery systems. This includes from regulatory agencies such as the U.S. Food and Drug Administration (FDA). What is the agreement? LTR Pharma advised that the agreement will encompass joint development and expertise, combining its pharmaceutical development capabilities with Aptar Pharma's expertise in nasal spray technology. The application for Spontan Nasal Spray will be filed in the US via the FDA's expedited regulatory pathway, which governs a change in route of administration of an already approved drug. In this case it is Levitra (Vardenafil) tablets. LTR Pharma recently completed its clinical trial to compare the pharmacokinetics, safety, and tolerability of Vardenafil following administration of Spontan nasal spray and Levitra tablets in healthy male adults. The trial showed that Spontan achieved a rapid absorption and faster onset of action compared to oral PDE5 inhibitors and delivered a similar amount of drug at half the dose of the oral PDE5 tablet. Following the success of this clinical trial, medical providers have started prescribing Spontan in Australia under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS). Commenting on the agreement, the ASX small cap's chair, Lee Rodne, said:  We are delighted to enter into a Co-Development Agreement with Aptar Pharma – a respected and experienced partner in our imminent goal to obtain regulatory approval for Spontan and to expand its global market reach and impact. As part of this, we will gain access to Aptar's expertise in the VP7 nasal spray system and related specialised services to support our FDA application process. This vastly de-risks the FDA application process and elevates the profile of LTR Pharma as a long-term partner of a global market innovator, which we anticipate may create opportunities for other products with alternative indications in future.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2459691146"}